[Ip-health] XTANDI rejected patent decision and oppositions on Patent Opposition Database

Shailly Gupta shailly.gupta at geneva.msf.org
Wed Nov 16 01:57:00 PST 2016

Dear All,

As you know, Indian patent office recently rejected Pfizer’s application for XTANDI (enzalutamide) used for the treatment of prostate cancer. 

http://health.economictimes.indiatimes.com/news/pharma/patent-denied-price-of-prostate-cancer-drug-may-go-down/55344613 <http://health.economictimes.indiatimes.com/news/pharma/patent-denied-price-of-prostate-cancer-drug-may-go-down/55344613> 

We have uploaded the concerned patent application, key patent oppositions and patent office decision on patent opposition database. You can access all of these documents here:

https://www.patentoppositions.org/en/drugs/enzalutamide <https://www.patentoppositions.org/en/drugs/enzalutamide>



Shailly Gupta
MSF Access Campaign
New Delhi

More information about the Ip-health mailing list